Nasal Cavity and Paranasal Sinus Cancer: Diagnosis and Treatment.

IF 4.7 2区医学 Q1 ONCOLOGY

Current Oncology Reports Pub Date : 2024-09-01 Epub Date: 2024-06-27 DOI:10.1007/s11912-024-01566-x

Frodita Jakimovska, Igor Stojkovski, Elena Kjosevska

{"title":"Nasal Cavity and Paranasal Sinus Cancer: Diagnosis and Treatment.","authors":"Frodita Jakimovska, Igor Stojkovski, Elena Kjosevska","doi":"10.1007/s11912-024-01566-x","DOIUrl":null,"url":null,"abstract":"Purpose of review: The purpose of this review is to analyze the diagnosis and treatments of the sinonasal malignant tumors throw systematic reviewed literature. The systematic review of the literature was performed according to PRISMA guidelines.Recent findings: Total 11,653 cases of five article were analyzed. The cohort of 3824 cases received appropriate treatment. The most frequent histotype of the group of sinonasal malignancies was squamous cell carcinoma. Squamous cell carcinoma was represented by 54%. The other histopathological subtypes were esthesioneuroblastoma with 9,9%, melanoma 9,8%, adenocarcinoma 7,5%, sarcoma 7,3%, adeno cystic carcinoma 7,1%, sinonasal undifferentiated carcinoma 3,9%, sinonasal neuroendocrine carcinoma 2,8% respectively. All 772 cases of total 3824 were treated only surgically. All 62 cases of total 3824 were treated without surgery, 20 cases with proton technique and SFUD, and 42 cases with proton technique and IMRT. The other 2990 cases of total 3824 were treated with multimodality treatment. The diagnosis and treatment of sinonasal cancers require a interdisciplinary approach and multimodality treatment.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":null,"pages":null},"PeriodicalIF":4.7000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Oncology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11912-024-01566-x","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/27 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: The purpose of this review is to analyze the diagnosis and treatments of the sinonasal malignant tumors throw systematic reviewed literature. The systematic review of the literature was performed according to PRISMA guidelines.

Recent findings: Total 11,653 cases of five article were analyzed. The cohort of 3824 cases received appropriate treatment. The most frequent histotype of the group of sinonasal malignancies was squamous cell carcinoma. Squamous cell carcinoma was represented by 54%. The other histopathological subtypes were esthesioneuroblastoma with 9,9%, melanoma 9,8%, adenocarcinoma 7,5%, sarcoma 7,3%, adeno cystic carcinoma 7,1%, sinonasal undifferentiated carcinoma 3,9%, sinonasal neuroendocrine carcinoma 2,8% respectively. All 772 cases of total 3824 were treated only surgically. All 62 cases of total 3824 were treated without surgery, 20 cases with proton technique and SFUD, and 42 cases with proton technique and IMRT. The other 2990 cases of total 3824 were treated with multimodality treatment. The diagnosis and treatment of sinonasal cancers require a interdisciplinary approach and multimodality treatment.

Abstract Image

查看原文本刊更多论文

鼻腔和副鼻窦癌：诊断与治疗。

综述目的：本综述旨在分析鼻窦鼻腔恶性肿瘤的诊断和治疗方法。根据 PRISMA 指南对文献进行了系统回顾：共分析了五篇文献中的 11653 个病例。其中 3824 例接受了适当的治疗。鼻窦恶性肿瘤中最常见的组织类型是鳞状细胞癌。鳞状细胞癌占 54%。其他组织病理学亚型包括：血管神经母细胞瘤（9.9%）、黑色素瘤（9.8%）、腺癌（7.5%）、肉瘤（7.3%）、腺囊性癌（7.1%）、鼻窦未分化癌（3.9%）、鼻窦神经内分泌癌（2.8%）。在总共 3824 个病例中，有 772 个病例只接受了手术治疗。在总共 3824 个病例中，有 62 例未经手术治疗，20 例采用质子技术和 SFUD 治疗，42 例采用质子技术和 IMRT 治疗。另外 3 824 例中的 2 990 例采用了多模式治疗。鼻窦癌的诊断和治疗需要跨学科方法和多模式治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Oncology Reports ONCOLOGY-

CiteScore

8.50

自引率

0.00%

发文量

187

审稿时长

6-12 weeks

期刊介绍： This journal aims to review the most important, recently published clinical findings in the field of oncology. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care of those affected by cancer. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as cancer prevention, leukemia, melanoma, neuro-oncology, and palliative medicine. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.